Wesson DE, Simoni J, Broglio K, Sheather S. Acid retention accompanies reduced GFR in humans and increases plasma levels of endothelin and aldosterone.
-Dietary alkali slows GFR decline in humans with a moderately reduced glomerular filtration rate (GFR) despite the absence of metabolic acidosis. Similarly, dietary alkali slows GFR decline in animals with 2/3 nephrectomy (Nx), a chronic kidney disease (CKD) model without metabolic acidosis in which GFR decline is mediated by acid (H ϩ ) retention through endothelin (ET) and mineralocorticoid receptors. To gain insight as to whether this mechanism might mediate GFR decline in humans, we explored whether macroalbuminuric subjects with moderately reduced (CKD stage 2 ϭ 60 -90 ml/min; CKD 2) compared with normal estimated GFR (Ͼ90 ml/min; CKD 1), each without metabolic acidosis, have H ϩ retention that increases plasma levels of ET-1 and aldosterone. Baseline plasma ET and aldosterone concentrations were each higher in CKD 2 than CKD 1. Baseline dietary H ϩ and urine net acid excretion (NAE) were not different between groups, but an acute oral NaHCO3 bolus reduced urine NAE less (i.e., postbolus urine NAE was higher) in CKD 2 than CKD 1, consistent with greater H ϩ retention in CKD 2 subjects. Thirty days of oral NaHCO3 reduced H ϩ retention in CKD 2 but not CKD 1 subjects and reduced plasma ET and aldosterone in both groups but to levels that remained higher in CKD 2 for each. Subjects with CKD stage 2 eGFR and no metabolic acidosis nevertheless have H ϩ retention that increases plasma ET and aldosterone levels, factors that might mediate subsequent GFR decline and other untoward vascular effects. acidosis; bicarbonate; chronic kidney disease; diet HEALTHCARE PROVIDERS FOCUS kidney-protective measures on chronic kidney disease (CKD) subjects with a severely reduced glomerular filtration rate (GFR) because of the more imminent threat of complete kidney failure (1) , but the largest CKD cadre has moderately reduced GFR (7) , in whom kidney-protective interventions likely have the greatest benefit. Those with hypertensive nephropathy can have progressive GFR decline despite blood pressure reduction with renin-angiotensin system inhibition (4, 16) . Although amelioration of metabolic acidosis in subjects with severely reduced GFR with oral NaHCO 3 (9) or Na ϩ citrate (21) slows decline rates of creatinine clearance (9) and estimated (e) GFR (21) , respectively, oral NaHCO 3 slowed eGFR decline in subjects with moderately reduced GFR without metabolic acidosis (16) . How oral NaHCO 3 slows GFR decline in subjects with moderately reduced GFR but no metabolic acidosis is not known.
Animals with 5/6 nephrectomy (Nx) have GFR decline (12, 22) induced by metabolic acidosis (22) and ameliorated by dietary alkali (22) . Endothelin (ET) mediates GFR decline (22) , and aldosterone mediates glomerulosclerosis (3, 11) in 5/6 Nx with metabolic acidosis. Animals with 2/3 as opposed to 5/6 Nx have no metabolic acidosis yet have GFR decline that is ameliorated by dietary alkali (36, 37) . These 2/3 Nx animals therefore model subjects with moderately reduced GFR without metabolic acidosis in which dietary alkali slowed GFR decline rate (16) . Progressive GFR decline in 2/3 Nx without metabolic acidosis is induced by H ϩ retention (36, 37) mediated through ET and aldosterone receptors (37) . Consequently, GFR decline in subjects with moderately reduced GFR (16) might be due to an H ϩ retention-induced increase in ET and aldosterone action. Because diets in industrialized societies are largely H ϩ inducing (26) and even subjects with normal GFR fail to completely excrete an increment of dietary H ϩ (14), those with moderately reduced GFR might have greater H ϩ retention.
We compared macroalbuminuric (urine albumin-to-creatinine ratio Ͼ200 mg/g) hypertensive nephropathy subjects with moderately reduced (CKD stage 2 ϭ eGFR 60 -90 ml/min; CKD 2) and normal eGFR (Ͼ90 ml/min; CKD 1) to explore whether CKD 2 subjects have 1) H ϩ retention; 2) higher plasma ET-1 and aldosterone levels; and 3) whether chronic daily NaHCO 3 lowers H ϩ retention and plasma levels of ET and aldosterone.
MATERIALS AND METHODS
This placebo-controlled, blinded interventional study gave bolus and daily oral NaHCO3 or NaCl (the latter to control for Na ϩ intake) to macroalbuminuric CKD 2 and CKD 1 subjects by a Modification of Diet in Renal Disease Study Group (MDRD) formula (13) due to hypertensive nephropathy to determine whether CKD 2 subjects had H ϩ retention, increased plasma ET and aldosterone levels, and whether daily NaHCO 3 reduced both. Our local Institutional Review Board (IRB) approved the study protocols. We excluded subjects with metabolic acidosis [plasma total CO 2 (TCO2) Ͻ24.5 mM, the lower limit of normal for our laboratory]. Four groups were studied: 1) 26 CKD 1 subjects; 2) 40 CKD 2 subjects who received only placebo (control cohort); 3) 40 CKD 2 subjects who received NaHCO 3 interventions (NaHCO3 cohort); and 4) 40 CKD 2 subjects who received NaCl interventions (NaCl cohort). Each treatment group is shown in Figs. 1 and 2 . CKD 1 subjects received placebo, bolus NaHCO 3, bolus NaCl, 30 days of daily NaHCO3 (chronic NaHCO3) and a second bolus NaHCO3 after 30 days of daily NaHCO3 (chronicϩbolus NaHCO3). CKD 2 subjects in the control cohort received only placebo. Subjects in the CKD 2 NaHCO 3 cohort received bolus NaHCO3, chronic NaHCO3, and chronicϩbolus NaHCO 3. CKD 2 subjects in the NaCl cohort received bolus NaCl, 30 days of daily NaCl (chronic NaCl), and bolus NaHCO 3 following the 30 days of NaCl (chronic NaClϩbolus NaHCO3). Other inclusion criteria were 1) nonmalignant hypertension; 2) 60 ՆeGFR Ͻ90 ml/min for the experimental group, Ͼ90 ml/min for controls; 3) Ն2 primary care physician visits in the preceding year, showing compliance with clinic visits; 4) age Ն18 yr and able to give consent. Exclusion criteria were 1) primary kidney disease or findings consistent thereof such as Ն3 red blood cells per high-powered field of urine or urine cellular casts; 2) history of diabetes or fasting blood glucose Ն110 mg/dl; 3) history of malignances, chronic infections, pregnancy, or clinical evidence of cardiovascular disease; and 4) peripheral edema or diagnoses associated with edema such as heart/liver failure or nephrotic syndrome. The diagnosis of hypertensive nephropathy as the exclusive cause of nephropathy was made clinically by excluding subjects with systemic diseases associated with nephropathy, nephroticrange proteinuria, and urine abnormalities other than albuminuria. None had a kidney biopsy. Secondary causes of hypertension such as renal artery stenosis and hyperaldosteronism were excluded clinically. Kidney Doppler studies and plasma aldosterone-to-renin ratios were not done. Subjects were recruited as described (16) . All subjects were treated toward a systolic blood pressure of Ͻ130 mmHg with regimens including angiotensin-converting enzyme inhibitors as recommended for those with albuminuria (6) .
For the 30 days of daily NaHCO 3 or NaCl, groups received identically appearing, scored tablets of sucrose (placebo group), sucroseϩNaHCO 3, or sucroseϩNaCl (Fig. 1) . The salt-containing tablets had 10 meq of either NaHCO3 or NaCl. Each subject was prescribed tablets to the nearest one-half tablet by body weight in kilograms (e.g., a 70-kg subject received 3.5 tablets daily) so that subjects received 0.5 meq/kg lean body wt of NaHCO 3 or NaCl daily for 30 days to examine effects of chronic NaHCO3 on H ϩ retention and plasma ET (PET), urine ET excretion (UET), plasma aldosterone (P aldo), and urine aldosterone excretion (Ualdo). Both subjects and personnel dispensing the tablets were blinded as to the type of tablet prescribed. For bolus NaHCO3 or bolus NaCl measurements, subjects received 0.5 meq/kg lean body wt of NaHCO3 or NaCl to measure H ϩ retention (see below). Our IRB permitted this comparatively low (20) dose because of concerns for volume retention and/or worsening hypertension due to the Na ϩ load.
Eight-hour urine net acid excretion (NAE) was measured and calculated from urine titratable acidity (TA), ammonium (NH 4 ϩ ), and (21) . Blood pressure was reduced pharmacologically toward recommended levels (6), as described (24) .
We assessed steady-state H ϩ retention by measuring 8-h NAE and venous TCO2 in CKD 2 and CKD 1 subjects after an oral 0.5-meq/kg lean body wt bolus of NaHCO3, NaCl, or placebo (Fig. 2 ). Subjects were told to take nothing by mouth after midnight except for medications before reporting when they voided to empty, had venous blood drawn for pH, PCO 2, and TCO2, and had venous access established. They were given the bolus at 8:00 a.m., had urine collected for NAE until 4:00 p.m., after which venous blood was drawn for acid-base parameters. They received eight ounces of chilled distilled H 2O, but no other intake, every 2 h to promote urine output. Our assessment of H ϩ retention assumed that higher H ϩ retention in CKD 2 subjects would manifest by greater H ϩ titration of the administered HCO3, reflected by less reduction of urine NAE (i.e., higher NAE compared with the respective baseline) without a greater increase in plasma TCO 2 (the latter would be more consistent with greater retention of intact HCO3 rather than its titration to CO2 and H2O by retained H ϩ ) than in CKD 1. This method assumes similar space of distribution between CKD 2 and CKD 1, a reasonable assumption given nearly identical plasma pH between groups (2). This method also assumes similar buffering capacity between CKD 2 and CKD 1, an assumption supported by no differences in levels of the major contributors to whole blood buffer base capacity (RESULTS). Because measured parameters did not permit comparison of intracellular buffering capacity, we assumed this parameter to be similar between CKD 2 and CKD 1.
Analytic methods. Plasma and urine creatinine and urine albumin were measured using a Sigma Diagnostics Creatinine Kit (procedure no. 555, Sigma Diagnostics) (24) . The IRMA SL Series 2000 blood analysis system (Edison, NJ) measured venous plasma/blood pH and PCO 2. Urine and plasma TCO2 were measured using ultrafluoremetry (30) . Urine TA was measured by correction to the ambient plasma pH by NaOH addition, NH 4 ϩ by the formalin titrametric (to ambient plasma pH) method (8) . PET and UET were measured with an RIA kit (Peninsula Laboratories, Belmont, CA) after extraction using Bound Elut C 18 columns (Varian, Harbor City, CA) (31). Plasma and urine aldosterone were measured after extraction with Bound Elut C18 columns (Varian) using a radioimmunoassay kit (Diagnostic Products, Los Angeles, CA) as done previously (37) . UET and aldosterone excretion were expressed per gram creatinine of a spot specimen (a.m.). Potential renal acid load (PRAL) was measured using a 3-day dairy assessment of the type and amount of foods ingested and scoring them as to their H ϩ or base content as described (25) . Statistical methods. The primary outcome was UET in response to chronic NaHCO 3. Secondary outcomes included PET, Paldo, Ualdo, urine 8-h NAE, venous pH, TCO2, and PCO2. We first compared demographic characteristics between CKD 2 and CKD 1 subjects with the 2 -test or two sample t-tests, as appropriate. Outcomes were compared between the CKD 1 subjects and the corresponding CKD 2 cohort at each intervention time with linear regression models that included terms for GFR group, age, sex, and ethnicity. Among CKD 2 subjects, we compared outcomes in the NaHCO 3 cohort and the NaCl cohort at each intervention time with the control cohort with linear regression models that included terms for cohort, age, sex, and ethnicity. Among CKD 1 subjects, we compared the outcomes at each intervention time point to the control time point with linear mixed models, often described as multilevel models (27) , because measurements were repeated within subjects in this group. In general, repeated measurements within subjects are more alike than measurements from different subjects. Another way to say this is that measurements within subjects are generally correlated. Thus an important choice in mixed models is the error/correlation structure within each subject, which in this case was modeled using a general symmetric structure. Each model included terms for age, sex, and ethnicity. Similarly, we used linear mixed models to compare baseline and 8-h values within each group for venous pH, PCO 2, and TCO2. All statistical tests are two-sided. No adjustments were made for multiple statistical tests, and P values Ͻ0.05 are considered statistically significant. Analyses were performed in R 2.4 (R Core Development Team).
RESULTS
There were a total of 120 subjects in the CKD 2 and 26 in the CKD 1 groups, and Table 1 shows their baseline characteristics. Age and gender were not significantly different between groups, but the proportion of white subjects was significantly higher in the CKD 1 group than in CKD 2. Nevertheless, data analyses to follow were not qualitatively different when only nonwhite subjects were considered, as was the case with a similar cohort in earlier studies from this laboratory (16) . MDRD eGFR was lower in CKD 2 than CKD 1 (75.6 Ϯ 6.2 vs. 100.8 Ϯ 8.5 ml/min, respectively, P Ͻ 0.0001) as per study design. PRAL, a measure of dietary H ϩ , was not significantly different between groups. There were also no differences in non-angiotensin-converting enzyme, nondiuretic drugs between CKD 2 and CKD 1 subjects. Table 2 shows that venous pH, PCO 2 , and TCO 2 were not significantly different between CKD 2 and CKD 1 before (0 h) and 8 h after receiving placebo. There were also no significant differences between the two groups in the 0-to 8-h difference in venous pH, PCO 2 , or TCO 2 . Similarly, 8-h NAE was not significantly different between the two groups. Table 3 shows venous pH, PCO 2 , and TCO 2 in the groups at 0 h and then 8 h after bolus NaHCO 3 (0.5 meq/kg body wt). Eight-hour NAE was statistically significantly higher in the CKD 2 NaHCO 3 cohort than CKD 1 after bolus NaHCO 3 . Because the increase in TCO 2 in response to NaHCO 3 bolus was not higher in CKD 2 than CKD 1 (in fact, Table 3 shows that the TCO 2 increase in CKD 2 is statistically significantly lower), higher 8-h NAE in CKD 2 after the same NaHCO 3 bolus is not consistent with greater retention of intact HCO 3 but is more consistent with greater HCO 3 titration by greater H ϩ retention in CKD 2. The method of assessing retained H ϩ assumes similar buffering capacity between CKD 2 and CKD 1. The major contributors to whole blood buffer base capacity were not different in CKD 2 and CKD 1, including plasma TCO 2 (Tables 2 and 3) , hemoglobin (14.5 Ϯ 0.4 vs. 14.6 Ϯ 0.5 g/dl, P ϭ 0.99), total plasma proteins (7.0 Ϯ 0.14 vs. 7.1 Ϯ 0.15 g/dl, P ϭ 0.12), and plasma PO 4 (3.1 Ϯ 0.31 vs. 3.0 Ϯ 0.30 g/dl, P ϭ 0.21). These data support similar buffering capacity between CKD 2 and CKD 1. Table 4 shows the same measures for the CKD 2 NaCl cohort and CKD 1 after bolus NaCl. Eight-hour NAE was not significantly different in the CKD 2 NaCl cohort than CKD 1 after the NaCl bolus. Nevertheless, 8-h NAE in CKD 2 after NaCl bolus was still higher than 8-h NAE following the NaHCO 3 bolus in CKD 2 (P ϭ 0.0003). These data support Values for age and potential renal acid load (PRAL) are means Ϯ SD; n ϭ 26 for CKD 1 and 120 for CKD 2. CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate.
that the lowered 8-h NAE in CKD 2 after the NaHCO 3 bolus (Table 3 ) was mediated by the administered HCO 3 , and not by the administered Na ϩ . Table 5 shows venous pH, PCO 2 , and TCO 2 in the CKD 2 NaHCO 3 cohort and CKD 1 at 0 h and 8-h after 30 days of daily oral NaHCO 3 (chronic NaHCO 3 ) at 0.5 meq/kg body wt/day followed by bolus NaHCO 3 . Eight-hour NAE was significantly higher in the CKD 2 NaHCO 3 cohort than CKD 1 after the NaHCO 3 bolus, consistent with greater H ϩ retention in CKD 2. Nevertheless, 8-h NAE in these CKD 2 subjects receiving chronic NaHCO 3 then the acute NaHCO 3 bolus was still lower than 8-h NAE following the same NaHCO 3 bolus given to the CKD 2 NaHCO 3 subjects who had no chronic NaHCO 3 (P Ͻ 0.001) but was higher than 8-h NAE in CKD 1 who had chronic then bolus NaHCO 3 (P Ͻ 0.0001). The latter data are consistent with lower H ϩ retention in CKD 2 than before chronic NaHCO 3 but also with persistently higher H ϩ retention than CKD 1 subjects who also had 30 days of NaHCO 3 . Table 6 shows the analogous data in the CKD 2 NaCl cohort when the same NaHCO 3 bolus was given after 30 days of oral NaCl (chronic NaCl). This group was used as a control to the chronic NaHCO 3 to control for the Na ϩ intake that accompanies NaHCO 3 . Eight-hour NAE in the CKD 2 NaCl cohort after chronic NaCl followed by bolus NaHCO 3 was not statistically different from 8-h NAE in the CKD 2 NaHCO 3 cohort (Table 3 ) who received no chronic NaCl or chronic NaHCO 3 but was significantly higher than 8-h NAE in the CKD 2 NaHCO 3 cohort after chronic NaHCO 3 followed by bolus NaHCO 3 (P Ͻ 0.0001). These data support that the reduction in H ϩ retention associated with chronic NaHCO 3 was due to HCO 3 and not to the associated Na ϩ intake. Figure 3 displays box plots of the course of PET in response to chronic (30 days) NaHCO 3 in CKD 2 and CKD 1 and in response to chronic NaCl in CKD 2. Baseline PET (mean Ϯ SD) was higher in the CKD 2 control cohort than CKD 1 (4.8 Ϯ 0.4 vs. 3.0 Ϯ 0.2 pg/ml, respectively, P Ͻ 0.0001). After chronic NaHCO 3 , PET for CKD 2 (3.9 Ϯ 0.5 pg/ml) and CKD 1 (2.9 Ϯ 0.2 pg/ml) were significantly lower than respective controls in both groups (P Ͻ 0.0001 for CKD 2 and CKD 1), but PET remained higher in CKD 2 than CKD 1 (P Ͻ 0.0001). Figure 3 also shows that PET for the CKD 2 cohort after chronic NaCl (4.8 Ϯ 0.4) was not significantly different from the CKD 2 control cohort (P ϭ 0.39), supporting that chronic HCO 3 but not chronic Na ϩ ingestion decreased PET in the CKD 2 cohort that received chronic NaHCO 3 . Figure 4 shows the course of kidney ET production measured by UET in box plots. Baseline UET was higher in the CKD 2 control cohort than CKD 1 (5.5 Ϯ 1.2 vs. 3.5 Ϯ 1.7 ng/g creatinine, respectively, P Ͻ 0.0001). After chronic NaHCO 3 , UET was significantly lower in CKD 2 (4.9 Ϯ 1.2 ng/g creatinine) and Ͼ90 (3.3 Ϯ 1.6 ng/g creatinine) groups than respective controls (P ϭ 0.028 for CKD 2 and P Ͻ 0.0001 for CKD 1), but UET remained higher in the CKD 2 NaHCO 3 cohort than CKD 1 (P Ͻ 0.0001). Figure 4 also shows that UET was not significantly different between the CKD 2 NaCl (5.4 Ϯ 1.3 ng/g creatinine) cohort after chronic NaCl and the Values are means Ϯ SD; n ϭ 26 for CKD 1 and 40 for CKD 2 NaHCO3 cohort.
CKD 2 control cohort (P ϭ 0.761), supporting that chronic HCO 3 but not chronic Na ϩ decreased UET. Figure 5 displays box plots of the course of P aldo in response to chronic (30 days) NaHCO 3 in CKD 2 and CKD 1 and in response to chronic (30 days) of NaCl in CKD 2. Baseline P aldo (means Ϯ SD) was higher in CKD 2 control cohort than CKD 1 (92.5 Ϯ 10.2 vs. 59.6 Ϯ 9.5 pg/ml, respectively, P Ͻ 0.0001). After chronic NaHCO 3 , P aldo for CKD 2 (72.4 Ϯ 7.3 pg/ml) and CKD 1 (57.6 Ϯ 7.7 pg/ml) were significantly lower than their respective controls in both groups (P Ͻ 0.0001 for both CKD 2 and P ϭ 0.0001 for CKD 1) but P aldo remained higher in the CKD 2 than CKD 1 cohort (P Ͻ 0.0001). Figure 5 also shows that P aldo was significantly lower in the CKD 2 NaCl (82.7 Ϯ 6.8 pg/ml) cohort after chronic NaCl than the CKD 2 control cohort (P Ͻ 0.0001) but was higher than after chronic NaHCO 3 (P Ͻ 0.0001). These data support that both chronic NaHCO 3 and chronic NaCl lowered P aldo but that chronic NaHCO 3 lowered P aldo more than did chronic NaCl. Figure 6 displays box plots of the course of urine aldosterone-to-creatinine ratio (U aldo ). Baseline U aldo was higher in the CKD 2 control cohort compared with CKD 1 (36.7 Ϯ 8.7 vs. 13.1 Ϯ 2.8 g/g creatinine, respectively, P Ͻ 0.0001). After chronic NaHCO 3 , U aldo was significantly lower in CKD 2 (25.7 Ϯ 5.9 g/g creatinine) and CKD 1 (11.7 Ϯ 2.0 g/g creatinine) than their respective controls (P Ͻ 0.0001 for CKD 2 and P ϭ 0.0001 for CKD 1), but U aldo remained higher in the CKD 2 NaHCO 3 cohort (P Ͻ 0.0001). Figure 6 also shows that U aldo was significantly lower in the CKD 2 NaCl (32.7 Ϯ 8.4
g/g creatinine) cohort after chronic NaCl than the CKD 2 control cohort (P ϭ 0.038). The data show that both chronic NaCl and chronic NaHCO 3 lowered U aldo but that U aldo was less in CKD 2 after chronic NaHCO 3 than after chronic NaCl (P Ͻ 0.0001).
DISCUSSION
Although metabolic acidosis contributes to the decline of creatinine clearance (9) and eGFR (21) in subjects with severely reduced GFR, mechanisms for GFR decline in those with moderately reduced GFR (4, 16) without metabolic acidosis (16) have not been determined. Subjects with moderately reduced GFR without metabolic acidosis and animals with 2 ⁄3 Nx with better preserved GFR than 5 ⁄6 Nx subjects experience GFR decline despite no metabolic acidosis (36, 37) . Progressive GFR decline in 2 ⁄3 Nx is mediated by H ϩ retention (36, 37) through augmented kidney ET and aldosterone action (37) and is ameliorated by dietary alkali (36, 37) . Because oral NaHCO 3 slows GFR decline in subjects with moderately reduced eGFR without metabolic acidosis (16), we explored whether subjects with moderately reduced eGFR have H ϩ retention that increases plasma levels of ET and/or aldosterone. The data support that subjects with moderately reduced GFR have H ϩ retention that increases plasma levels of ET and aldosterone as well as increases their urine excretion, the latter consistent with increased kidney ET and aldostreone levels. The increased plasma levels and urine excretion of ET and aldosterone were Values are means Ϯ SD; n ϭ 26 for CKD 1 and 40 for CKD 2 NaHCO3 cohort.
ameliorated by 30 days of oral NaHCO 3 . These data suggest that NaHCO 3 -induced slowing of eGFR decline in subjects with moderately reduced GFR (16) was due to amelioration of H ϩ retention with reduction of ET-1 and aldosterone activity. Further studies will be needed to test this hypothesis.
Daily NH 4 Cl in humans induced urine NAE that was less than the increment in H ϩ production, consistent with H ϩ retention despite steady-state plasma HCO 3 concentration (14) . Subjects likely maintained normal or near normal plasma acid-base parameters despite H ϩ retention through H ϩ titration of body buffers (15) . Because humans in industrialized societies eat diets that are largely H ϩ inducing (26), they are continually challenged with dietary H ϩ . Indeed, animals with intact nephron mass that ate an H ϩ -inducing diet maintained plasma acid-base parameters comparable to control yet had steady-state H ϩ retention measured by microdialysis (32) and had kidney injury (35) that was each ameliorated by dietary alkali (32, 35) . Nevertheless, subjects with presumably normal GFR who ate diets typical of industrialized societies had mild metabolic acidosis that, when neutralized with oral NaHCO 3 , ameliorated bone resorption (18) . Although plasma pH, PCO 2 , and TCO 2 of CKD 2 were not statistically different from CKD 1, each was numerically lower in CKD 2 and so we cannot definitively exclude mild metabolic acidosis in CKD 2.
These studies support that CKD 2 subjects had H ϩ retention but did not determine mechanisms by which it occurred.
Continued ingestion of dietary H
ϩ when GFR declines might increase H ϩ retention in the interval during which kidneys complete adjustments to increase per nephron acidification (34) and thereby increase overall H ϩ excretion in an effort to better maintain body acid-base balance in the setting of reduced GFR (10) . Subjects with intact GFR excrete less H ϩ than the increment in dietary H ϩ -induced intrinsic H ϩ production (14), supporting H ϩ retention in this setting. In an animal model of this setting, increasing dietary H ϩ in animals with intact nephron mass caused H ϩ retention measured directly with microdialysis that did not return to baseline levels until the increment in dietary H ϩ was stopped (32) . We propose that in response to GFR reduction with continued dietary H ϩ intake, kidney adjustments increase overall kidney H ϩ excretion sufficient to maintain normal plasma acid-base parameters (38) but not to completely correct the increment in H ϩ retention. Consequently, we propose that CKD 2 ingesting H ϩ -inducing diets typical of industrialized societies, like 2 ⁄3 Nx animals ingesting H ϩ -inducing diets (36, 37) , have sufficient remaining GFR that enables them to achieve a steady state of normal plasma acid-base parameters but at the cost of increased H ϩ retention. The present studies show that 30 days of oral Values are means Ϯ SD; n ϭ 40 for CKD 2 NaCl cohort. NaHCO 3 at 0.5 meq·kg lean body wt Ϫ1 ·dayϪ1 lowered H ϩ retention in CKD 2 subjects but H ϩ retention remained higher in CKD 2 than CKD 1. These data suggest that 30 days of oral NaHCO 3 as dosed did not lower H ϩ retention to the level of CKD 1 subjects. A higher NaHCO 3 dose, possibly 1.0 meq·kg lean body wt Ϫ1 ·day Ϫ1 HCO 3 equivalent·day Ϫ1 recommended for CKD with plasma TCO 2 Ͻ22 mM (20) , longer treatment at the lower dose, or a less H ϩ -inducing diet, might restore H ϩ retention in CKD 2 to the level in CKD 1. Despite the data supporting the presence of H ϩ retention, CKD 2 subjects had plasma acid-base parameters that were not different from CKD 1 subjects. This is identical to the situation in 2 ⁄3 Nx animals which have plasma acid-base parameters no different from those with intact nephron mass yet have H ϩ retention demonstrated using microdialysis of kidney cortex (36, 37) and skeletal muscle (36) . Finding H ϩ retention in both kidney cortex and skeletal muscle supports that H ϩ retention in these animals is a systemic and not just a local phenomenon. Furthermore, animals with intact nephron mass given chronic dietary H ϩ had H ϩ retention yet had plasma acid-base parameters comparable to control (32) . This same dietary H ϩ protocol induced kidney injury in other animals with intact nephron mass, again with plasma acid-base parameters comparable to control (35) . Acid retention was reduced by adding dietary alkali (32, 36, 37) , but removing the increment of dietary H ϩ returned H ϩ retention to control levels (32, 36, 37) . Consequently, animals and humans given chronic dietary H ϩ and those with moderately reduced GFR behave as if they are carrying an increased H ϩ load that is not reflected in plasma acid-base parameters. We speculate that this "hidden" H ϩ is bound to body buffers (15) , predominantly intracellularly (29) . We further speculate that even greater H ϩ loads and/or much lower GFR creates a context that taxes body buffers to a greater degree, yielding measurable changes in plasma acid-base parameters. In support of this speculation, humans with moderate GFR reduction often have normal plasma acid-base parameters, and the risk for metabolic acidosis by plasma acid-base parameters increases as GFR declines (38) .
Although plasma acid-base parameters in CKD 2 were not different from CKD 1, subjects with CKD 2 appear to "sense" H ϩ retention as manifest by increased plasma levels and urine excretion of ET and aldosterone. In vitro studies show that an acid extracellular environment increases ET release from human glomerular endothelial cells (33) and that a more acid perfusate increases aldosterone release from isolated, perfused adrenal glands (23) . Consequently, CKD 2 subjects appear to be able to sense an aspect of retained H ϩ . Because plasma pH was not different between CKD 2 and CKD 1 subjects, and because there were no differences in intracellular pH in animals with increased protein catabolism due to metabolic acidosis (5), we speculate that plasma or intracellular pH is likely not a major contributing signal. If pH is indeed a signal, we suspect that it is the pH of a compartment like interstitial fluid, as speculated in earlier studies from our laboratory (32) and by other investigators studying the pH sensor GPR4 (28) . An additional consideration for a "sensing" system is one that senses the degree of buffer titration that stimulates a response, including increased plasma levels and urine excretion of ET and aldosterone. Further studies will be required to clarify this important question.
Because subjects with moderately compared with severely reduced GFR comprise the largest cadre with CKD (7) and because this group appears more likely to benefit from kidneyprotective interventions, subjects with moderately reduced GFR must continue to be a major focus of treatment interventions and continued investigation. The present studies support that subjects with hypertensive nephropathy and moderately reduced (CKD stage 2) eGFR have H ϩ retention with increased plasma levels of ET and aldosterone and increased urine excretion of ET and aldosterone (a surrogate of kidney levels of each). Thirty days of daily NaHCO 3 lowered H ϩ retention and lowered plasma levels and urine excretion of ET and aldosterone. Consequently, H ϩ retention with increased kidney ET and aldosterone production might contribute to progressive GFR decline in subjects with moderately reduced GFR, and chronic NaHCO 3 might be an effective adjunct to standard kidney protective strategies in these subjects. In the 2 ⁄3 Nx model of moderately reduced GFR without metabolic acidosis, dietary alkali better preserved GFR than either ET or aldosterone receptor antagonist alone or in combination (37) . If subsequent studies show that higher kidney activity of ET and/or aldosterone contributes to progressive GFR decline in humans with moderately reduced GFR, dietary alkali should be considered as a potentially a more effective, better-tolerated, and less-expensive kidney-protective intervention than ET (17) and aldosterone (19) antagonists being tested as kidneyprotective agents in subjects with reduced GFR.
These studies show that 30 days of oral NaHCO 3 lowered plasma levels each of ET and aldosterone in CKD 1 as well as CKD 2, the latter as hypothesized. These data raise the possibility that CKD 1 subjects also had H ϩ retention that was too small to be detected with the methods used. This possibility is supported by data showing that the increment in excreted H ϩ is less than the increment in dietary H ϩ , even with normal GFR (14) . Because of the H ϩ -inducing nature of diets in industrialized societies (26) , both CKD 1 and CKD 2 subjects might have H ϩ retention that is only greater in CKD 2. Study limitations include our indirect method of assessing H ϩ retention that has not been validated by others. In addition, only subjects with reduced GFR due to hypertensive nephropathy were studied, and so it is not known whether these findings apply to those with reduced GFR from other etiologies. Fig. 6 . Box plots showing urine aldosterone-to-creatinine ratio (Ualdo; g/g creatinine) in spot morning specimens from CKD 2 and CKD 1 subjects. Determinations were done at baseline, after 30 days of daily NaHCO3, and after 30 days of daily NaCl (the latter done in only CKD 2) as described. *P Ͻ 0.05 vs. respective CKD 1. ϩP Ͻ 0.05 vs. respective baseline within groups.
In summary, these studies show that subjects with CKD stage 2 eGFR due to hypertensive nephropathy have H ϩ retention with increased plasma levels of ET and aldosterone and increased urine excretion of both. Importantly, chronic daily NaHCO 3 lowers each. These and other recent studies encourage longer-term studies to determine whether H ϩ retention-induced ET and aldosterone action mediates GFR decline in subjects with moderately reduced GFR.
